1.Respiratory syncytial virus infection in hematopoietic stem cell transplantation recipients with primary immunodeficiencies.
Ping LIU ; Yao ZHAO ; Jian-wen XIAO ; Cui ZHANG ; Xiao-dong ZHAO
Chinese Journal of Pediatrics 2011;49(7):489-494
OBJECTIVETo understand the clinical characteristics and outcome associated with respiratory syncytial virus (RSV) infection in hematopoietic stem cell transplantation (HSCT) recipients with primary immunodeficiencies (PIDs).
METHODNasopharyngeal aspirate samples were collected consecutively before and after HSCT from 9 recipients from Apr. 2009 to Sep. 2010 and analyzed for the presence of RSV using real-time polymerase chain reaction assay. To further verify the presence of the virus, positive samples for PCR were isolated for RSV. RSV G gene was amplified, sequenced and used for phylogenetic analysis.
RESULTThe presence of RSV was detected in 3 out of 9 children. The viral replication in all the patients was prolonged for months. All the 3 patients with RSV infection were treated with intravenous immune globulin (IVIG) and one was treated with antiviral medication. All patients survived and achieved successful immune reconstitution.
CONCLUSIONThis study indicates that the HSCT recipients with PID are at increased risk for RSV infection. RSV can shed for months after the initial infection and the patients recover with the course of immune reconstitution.
Child, Preschool ; Female ; Hematopoietic Stem Cell Transplantation ; adverse effects ; Humans ; Immunologic Deficiency Syndromes ; surgery ; virology ; Infant ; Prognosis ; Respiratory Syncytial Virus Infections ; diagnosis ; drug therapy ; Respiratory Syncytial Viruses ; genetics ; isolation & purification ; physiology ; Virus Replication ; Virus Shedding
2.Protective efficacy of commercial inactivated Newcastle disease virus vaccines in chickens against a recent Korean epizootic strain.
Woo Jin JEON ; Eun Kyoung LEE ; Young Jeong LEE ; Ok Mi JEONG ; Yong Joo KIM ; Jun Hun KWON ; Kang Seuk CHOI
Journal of Veterinary Science 2008;9(3):295-300
Despite the intensive vaccination policy that has been put in place to control Newcastle disease virus (NDV), the recent emergence of NDV genotype VII strains in Korea has led to significant economic losses in the poultry industry. We ssessed the ability of inactivated, oil-emulsion vaccines derived from La Sota or Ulster 2C NDV strains to protect chickens from challenge with Kr-005/00, which is a recently isolated Korean epizootic genotype VII strain. Six-week-old SPF chickens were vaccinated once and challenged three weeks later via the eye drop/intranasal route. All vaccinated birds were fully protected from disease, regardless of the vaccine strains used. All vaccinated and challenged groups showed significant sero-conversion 14 days after challenge. However, some vaccinated birds, despite being protected from disease, shed the challenge virus from their oro-pharynx and cloaca, albeit at significantly lower titers than the unvaccinated challenged control birds. The virological, serological, and epidemiological significance of our observations with regard to NDV disease eradication is discussed.
Administration, Intranasal
;
Animals
;
Chickens
;
Cloaca/virology
;
Disease Outbreaks/prevention & control/*veterinary
;
Korea
;
Newcastle Disease/*immunology/prevention & control
;
Newcastle disease virus/*immunology
;
Ophthalmic Solutions
;
Poultry Diseases/*immunology/prevention & control
;
*Vaccines, Inactivated/administration & dosage
;
Viral Vaccines/*administration & dosage
;
Virus Shedding/drug effects
3.Interferon-α2b spray inhalation did not shorten virus shedding time of SARS-CoV-2 in hospitalized patients: a preliminary matched case-control study.
Shao-Rui HAO ; Ren YAN ; Shan-Yan ZHANG ; Jiang-Shan LIAN ; Huan CAI ; Xiao-Li ZHANG ; Lin ZHENG ; Hong-Yu JIA ; Jian-Hua HU ; Guo-Dong YU ; Jue-Qing GU ; Chan-Yuan YE ; Ci-Liang JIN ; Ying-Feng LU ; Jiao-Jiao XIN ; Ji-Fang SHENG ; Yi-Da YANG
Journal of Zhejiang University. Science. B 2020;21(8):628-636
BACKGROUND:
Currently, there are no drugs that have been proven to be effective against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Because of its broad antiviral activity, interferon (IFN) should be evaluated as a potential therapeutic agent for treatment of coronavirus disease 2019 (COVID-19), especially while COVID-19-specific therapies are still under development.
METHODS:
Confirmed COVID-19 patients hospitalized in the First Affiliated Hospital, School of Medicine, Zhejiang University in Hangzhou, China, from January 19 to February 19, 2020 were enrolled in a retrospective study. The patients were separated into an IFN group and a control group according to whether they received initial IFN-α2b inhalation treatment after admission. Propensity-score matching was used to balance the confounding factors.
RESULTS:
A total of 104 confirmed COVID-19 patients, 68 in the IFN group and 36 in the control group, were enrolled. Less hypertension (27.9% vs. 55.6%, P=0.006), dyspnea (8.8% vs. 25.0%, P=0.025), or diarrhea (4.4% vs. 19.4%, P=0.030) was observed in the IFN group. Lower levels of albumin and C-reactive protein and higher level of sodium were observed in the IFN group. Glucocorticoid dosage was lower in the IFN group (median, 40 vs. 80 mg/d, P=0.025). Compared to the control group, fewer patients in the IFN group were ventilated (13.2% vs. 33.3%, P=0.015) and admitted to intensive care unit (ICU) (16.2% vs. 44.4%, P=0.002). There were also fewer critical patients in the IFN group (7.4% vs. 25.0%, P=0.017) upon admission. Although complications during admission process were comparable between groups, the discharge rate (85.3% vs. 66.7%, P=0.027) was higher and the hospitalization time (16 vs. 21 d, P=0.015) was shorter in the IFN group. When other confounding factors were not considered, virus shedding time (10 vs. 13 d, P=0.014) was also shorter in the IFN group. However, when the influence of other factors was eliminated using propensity score matching, virus shedding time was not significantly shorter than that of the control group (12 vs. 15 d, P=0.206).
CONCLUSIONS
IFN-α2b spray inhalation did not shorten virus shedding time of SARS-CoV-2 in hospitalized patients.
Albumins/analysis*
;
Antiviral Agents/administration & dosage*
;
Betacoronavirus
;
C-Reactive Protein/analysis*
;
COVID-19
;
Case-Control Studies
;
China
;
Coronavirus Infections/drug therapy*
;
Glucocorticoids/pharmacology*
;
Hospitalization
;
Humans
;
Interferon alpha-2/administration & dosage*
;
Nasal Sprays
;
Pandemics
;
Pneumonia, Viral/drug therapy*
;
Propensity Score
;
Retrospective Studies
;
SARS-CoV-2
;
Sodium/blood*
;
Virus Shedding/drug effects*
;
COVID-19 Drug Treatment